Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KRYS – Krystal Biotech, Inc.

Krystal Biotech, Inc.
KRYS
$148.39
Name : Krystal Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $4,267,770,624.00
EPSttm : 1.78
finviz dynamic chart for KRYS
Krystal Biotech, Inc.
$148.39
2.47%
$3.58

Float Short %

13.86

Margin Of Safety %

58

Put/Call OI Ratio

0.55

EPS Next Q Diff

0.36

EPS Last/This Y

4.84

EPS This/Next Y

1.53

Price

148.5

Target Price

206.29

Analyst Recom

1

Performance Q

-16.53

Relative Volume

0.68

Beta

0.85

Ticker: KRYS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19KRYS160.860.8610.7210314
2024-12-20KRYS164.660.950.6611151
2024-12-23KRYS160.980.612.937379
2024-12-24KRYS158.520.610.007383
2024-12-26KRYS160.510.613.677383
2024-12-27KRYS159.650.630.107460
2024-12-30KRYS1600.620.007480
2024-12-31KRYS156.660.710.076933
2025-01-02KRYS156.10.670.027173
2025-01-03KRYS157.950.670.007178
2025-01-06KRYS155.70.670.187184
2025-01-07KRYS159.770.670.027208
2025-01-08KRYS156.720.660.007237
2025-01-09KRYS156.670.660.007237
2025-01-10KRYS152.90.660.147245
2025-01-13KRYS150.350.660.007318
2025-01-14KRYS142.850.530.998306
2025-01-15KRYS146.440.570.2711639
2025-01-16KRYS144.830.562.2211673
2025-01-17KRYS148.540.556.4011547
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19KRYS160.9893.589.25.24
2024-12-20KRYS164.7593.588.25.24
2024-12-23KRYS160.8393.574.15.24
2024-12-24KRYS158.5293.576.85.24
2024-12-26KRYS160.4993.584.75.24
2024-12-27KRYS159.6293.579.45.24
2024-12-30KRYS159.5893.581.65.24
2024-12-31KRYS156.9193.575.75.24
2025-01-02KRYS156.3793.580.55.24
2025-01-03KRYS157.8893.583.75.24
2025-01-06KRYS155.5593.575.95.24
2025-01-07KRYS159.8193.588.65.24
2025-01-08KRYS156.6793.575.45.24
2025-01-09KRYS156.6793.581.05.24
2025-01-10KRYS153.0893.574.35.24
2025-01-13KRYS150.3093.576.05.24
2025-01-14KRYS142.8893.566.45.24
2025-01-15KRYS146.4493.589.05.24
2025-01-16KRYS144.6793.577.45.24
2025-01-17KRYS148.5093.588.65.24
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19KRYS-4.31-1.9015.01
2024-12-20KRYS-4.31-1.9015.01
2024-12-23KRYS-4.21-1.9215.01
2024-12-24KRYS-4.21-1.9215.01
2024-12-26KRYS-4.37-1.9215.21
2024-12-27KRYS-4.31-1.9215.21
2024-12-30KRYS-4.34-1.9015.21
2024-12-31KRYS-4.34-1.9015.21
2025-01-02KRYS-4.39-1.9015.21
2025-01-03KRYS-4.31-1.9015.21
2025-01-06KRYS-4.26-1.9715.21
2025-01-07KRYS-4.26-1.9715.21
2025-01-08KRYS-4.31-1.9715.21
2025-01-09KRYS-4.31-1.9715.21
2025-01-10KRYS-4.31-1.9715.21
2025-01-13KRYS-4.31-1.9913.86
2025-01-14KRYS-4.31-1.9913.86
2025-01-15KRYS-4.31-1.9913.86
2025-01-16KRYS-4.31-1.9913.86
2025-01-17KRYS-4.31-1.9913.86
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.91

Avg. EPS Est. Current Quarter

1.85

Avg. EPS Est. Next Quarter

1.27

Insider Transactions

-4.31

Institutional Transactions

-1.99

Beta

0.85

Average Sales Estimate Current Quarter

91

Average Sales Estimate Next Quarter

91

Fair Value

234.33

Quality Score

74

Growth Score

44

Sentiment Score

7

Actual DrawDown %

32.3

Max Drawdown 5-Year %

-53.4

Target Price

206.29

P/E

83.95

Forward P/E

25

PEG

P/S

17.67

P/B

4.82

P/Free Cash Flow

73.51

EPS

1.77

Average EPS Est. Cur. Y​

5.24

EPS Next Y. (Est.)

6.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

21.68

Relative Volume

0.68

Return on Equity vs Sector %

-13.2

Return on Equity vs Industry %

-0.6

EPS 1 7Days Diff

1.5

EPS 1 30Days Diff

1.67

EBIT Estimation

88.6
Krystal Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 229
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading